ATE546527T1 - Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs - Google Patents

Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs

Info

Publication number
ATE546527T1
ATE546527T1 AT10003331T AT10003331T ATE546527T1 AT E546527 T1 ATE546527 T1 AT E546527T1 AT 10003331 T AT10003331 T AT 10003331T AT 10003331 T AT10003331 T AT 10003331T AT E546527 T1 ATE546527 T1 AT E546527T1
Authority
AT
Austria
Prior art keywords
cancer
liver cancer
dlk
detecting liver
antibody
Prior art date
Application number
AT10003331T
Other languages
English (en)
Inventor
Koji Nakamura
Hiroko Tanaka
Hiroyuki Yanai
Atsushi Miyajima
Original Assignee
Kanagawa Kagaku Gijutsu Akad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Kagaku Gijutsu Akad filed Critical Kanagawa Kagaku Gijutsu Akad
Application granted granted Critical
Publication of ATE546527T1 publication Critical patent/ATE546527T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT10003331T 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs ATE546527T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003399331 2003-11-28
JP2003401585 2003-12-01
JP2003423237 2003-12-19

Publications (1)

Publication Number Publication Date
ATE546527T1 true ATE546527T1 (de) 2012-03-15

Family

ID=34636972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10003331T ATE546527T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04819413T ATE466937T1 (de) 2003-11-28 2004-11-25 Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs

Country Status (8)

Country Link
US (2) US20080112956A1 (de)
EP (2) EP2204448B1 (de)
JP (1) JP4695982B2 (de)
AT (2) ATE546527T1 (de)
CA (1) CA2552553C (de)
DE (1) DE602004027085D1 (de)
ES (2) ES2382987T3 (de)
WO (1) WO2005052156A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
KR100964193B1 (ko) * 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커
SG10201503904XA (en) 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
EP2412792A1 (de) 2010-07-29 2012-02-01 The Procter & Gamble Company Flüssige Reinigungsmittelzusammensetzung
WO2012138100A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
PL2905335T3 (pl) 2012-10-03 2018-06-29 Chiome Bioscience Inc. Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo
ME03417B (de) 2014-05-15 2020-01-20 Eisai R&D Man Co Ltd Pladienolidpyridinverbindungen und verfahren zur verwendung
MX2018006155A (es) 2015-11-18 2018-08-01 Eisai R&D Man Co Ltd Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
CN110031629B (zh) * 2018-01-11 2020-08-18 上海交通大学 检测人血清dlk1蛋白的elisa试剂盒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013701A2 (en) * 1992-12-11 1994-06-23 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services Delta-like gene expressed in neuroendocrine tumors
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP4344231B2 (ja) * 2001-05-16 2009-10-14 財団法人神奈川科学技術アカデミー dlkを用いた未分化肝細胞の検出及び分離方法
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators

Also Published As

Publication number Publication date
JPWO2005052156A1 (ja) 2007-12-06
EP2204448B1 (de) 2012-02-22
ES2345493T3 (es) 2010-09-24
CA2552553A1 (en) 2005-06-09
WO2005052156A1 (ja) 2005-06-09
DE602004027085D1 (de) 2010-06-17
US20100151503A1 (en) 2010-06-17
EP1702982A1 (de) 2006-09-20
US20080112956A1 (en) 2008-05-15
ATE466937T1 (de) 2010-05-15
CA2552553C (en) 2015-01-06
ES2382987T3 (es) 2012-06-15
EP1702982B1 (de) 2010-05-05
JP4695982B2 (ja) 2011-06-08
EP1702982A4 (de) 2007-04-25
EP2204448A1 (de) 2010-07-07

Similar Documents

Publication Publication Date Title
ATE546527T1 (de) Verfahren zum nachweis von leberkrebs, diagnose auf leberkrebs und heilmittel gegen krebs
Park et al. Hydrochromic approaches to mapping human sweat pores
Fernández-Sánchez et al. Disposable noncompetitive immunosensor for free and total prostate-specific antigen based on capacitance measurement
Warren-Smith et al. Fluorescence-based aluminum ion sensing using a surface-functionalized microstructured optical fiber
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
CY1113686T1 (el) Συσκευη bio-αισθητηρα και οι μεθοδοι χρησης της
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
ATE519110T1 (de) Diagnostischer nanosensor und dessen verwendung in der medizin
EE05650B1 (et) Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
DE602007004666D1 (de) Verfahren zum analytennachweis unter verwendung von proximitätssonden
CY1115439T1 (el) Μεθοδοι και νουκλεϊκα οξεα για αναλυσεις διαταραχων του κυτταρικου πολλαπλασιασμου
ATE497602T1 (de) Hybride mikroauslegersensoren
Jamerlan et al. Advances in amyloid beta oligomer detection applications in Alzheimer's disease
Früh et al. Strain field self-diagnostic poly (dimethylsiloxane) elastomers
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
Kim et al. Voltammetric studies of topotecan transfer across liquid/liquid interfaces and sensing applications
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
ATE535620T1 (de) Entwicklung eines echtzeit-pcr-tests zum nachweis von pneumokokken-dna und diagnose einer pneumokokkenerkrankung
ATE511636T1 (de) Verfahren zum nachweis biologischer organismen mittels raman-streuung
WO2012050365A3 (ko) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
Polcari et al. Determination of the relationship between expression and functional activity of multidrug resistance-associated protein 1 using scanning electrochemical microscopy
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome